论文部分内容阅读
目的:研究分析Apo A5-1131bp T>C基因多态性与阿托伐他汀降脂作用的相关性。方法:选取2012年2月-2013年6月神经内科和心血管内科住院的血脂异常患者324例,采用多聚酶链反应-限制性片段长度多态性法进行基因型检测,并随机选取其中87名患者,口服阿托伐他汀10 mg/d,分析比较Apo A5-1131bp T>C各基因型的服药前后的血脂水平,同时收集所研究患者各项实验室指标、流行病学问卷等,并对所有研究数据进行统计分析。结果:服药前甘油三酯(TG)水平TC型组与CC型组明显高于TT型组,而以CC型组的TG水平最高,组间差异具有统计学意义(P<0.05);服药12周后发现C携带者的TG降低水平明显高于非C携带者,组间差异具有统计学意义(P<0.05),其余的血脂指标则没有此项发现。结论:Apo A5-1131bp T>C基因启动区基因多态性与血浆血脂水平存在一定关联,该位点T/C转换与高血脂有关。
OBJECTIVE: To study the relationship between Apo A5-1131bp T> C gene polymorphism and atorvastatin lipid-lowering effect. Methods: A total of 324 patients with dyslipidemia admitted to Department of Neurology and Cardiology from February 2012 to June 2013 were enrolled. Genotypes were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and 87 Patients were randomized to receive atorvastatin 10 mg / d. The levels of blood lipids in the Apo A5-1131bp T> C genotypes before and after treatment were analyzed. Various laboratory parameters and epidemiological questionnaires were collected and analyzed. All research data for statistical analysis. Results: Before treatment, triglyceride (TG) levels in TC group and CC group were significantly higher than those in TT group, while those in CC group were the highest, with statistical significance (P <0.05). Administration of 12 Week C found that carriers of TG decreased significantly higher than non-C carriers, the difference between groups was statistically significant (P <0.05), the remaining indicators of lipids were not found. CONCLUSION: Gene polymorphism of promoter region of Apo A5-1131bp T> C gene is correlated with plasma lipid level. T / C conversion of this locus is associated with hyperlipidemia.